Treatment of multiple myeloma

• Published in: Joint Bone Spine Vol. 70; no. 3; pp. 175 - 186
• Main Authors: Clerc, Didier, Fermand, Jean-Paul, Mariette, Xavier
• Format: Book Review Journal Article
• Language: English
• Published: France Elsevier SAS 01.06.2003
• Subjects: Antineoplastic Agents - therapeutic use; Bisphosphonates; Chemotherapy; Humans; Medical Oncology - methods; Multiple Myeloma - classification; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Myeloma; Myeloma; Bisphosphonates; Chemotherapy
• ISSN: 1297-319X
• DOI: 10.1016/S1297-319X(03)00018-6

Conventional chemotherapies are no longer the only treatment in multiple myelomatosis. High-dose chemotherapy and autologous transplantation are not curative but do increase relapse-free survival time in young patients. Thalidomide is efficacious in refractory and relapsing myeloma and its evaluation is going on. Curative and preventive treatments of skeletal events, infections and anemia improve quality of life. All together, these strategies imply therapeutic knowledge and choices but allow an about 5-year-long median survival time in modern studies. Treatment options for myeloma now include, not only conventional chemotherapy regimens, but also novel symptomatic drugs and strategies that increase survival and/or quality of life, although they fail to provide a cure. In parallel with this expansion of the treatment armamentarium, physicians must acquire the knowledge needed to select the best treatment for the individual patient. After reviewing the rationale, effectiveness, and safety of each of these treatments, we will discuss the indications that we believe are legitimate.